



ADMEDUS Ltd ABN 35 088 221 078

REGISTERED OFFICE:

Level 1, 197 Adelaide Terrace
Perth Western Australia 6000

PO Box 6879 East Perth
Western Australia 6892

T +61 (0)8 9266 0100
F +61 (0)8 9266 0199
E info.au@admedus.com

ANNOUNCEMENT TO THE AUSTRALIAN STOCK EXCHANGE

www.admedus.com

31st January 2014

Company Announcements Office
Australian Stock Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000

Dear Sir/Madam,

Re: Appendix 4C - Quarterly Report

Please refer to the 'Appendix 4C' attached for details for the period ended 31 December 2013 for the Group.

- **Company name change to Admedus Ltd**
- **Acquisition of a world-class manufacturing facility to support the scale-up of CardioCel®**
- **CardioCel® launched in Europe**
- **Admedus named Emerging Company of the Year**

Admedus secured sales of almost \$2M for the last quarter with total revenue for the half year over \$4M, which represents an increase from the previous year for the same period.

Admedus finished the quarter with over \$9M in cash reserves and remains in a strong cash position. During the period the Company concluded a \$10.4M Rights Issue.

Admedus also received another instalment of \$450,000 as part of its ongoing Commercialisation Australia grant, which is supported by the Australian Government.

The past quarter has been another productive one for the Company with several significant events which include:

- Eight surgeons from the Prince Charles Hospital in Brisbane approved to use CardioCel® under the Authorised Prescriber Scheme for adult patients. This is an important milestone for the company as it is the first authorised use of CardioCel® in adults, adding to its ongoing use in paediatric patients.
- Admedus was awarded the Ausbiotech "Emerging Company of the Year" award, sponsored by Janssen, at the annual Ausbiotech conference. This award recognises the significant progress the Company has made towards the commercialisation of CardioCel® and the benefits CardioCel® offers patients

- First sales of CardioCel®
CardioCel® was approved for sale in Europe earlier in the year and during the quarter initial sales were made with growing interest and demand from surgeons wanting to use the product in Europe.
- All patients participating in the Phase 1 HSV-2 vaccine study completed their dosing. Interim results are expected in February.

The company is looking forward to a strong second half of the financial year and is on track to see another increase in revenue compared to the previous year.

Yours sincerely

A handwritten signature in black ink, appearing to read 'S. Mann', written in a cursive style.

Stephen Mann
Company Secretary

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity

Admedus Limited

ABN

36 088 221 078

Quarter ended ("current quarter")

31 December 2013

Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$A'000	Year to date (6 months) \$A'000
1.1	Receipts from customers	1,950	4,148
1.2	Payments for		
	(a) staff costs	(1,642)	(2,764)
	(b) advertising and marketing	(117)	(194)
	(c) research and development	(976)	(1,829)
	(d) leased assets	-	-
	(e) other working capital	(2,243)	(4,264)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	16	17
1.5	Interest and other costs of finance paid	(16)	(17)
1.6	Income taxes paid	-	-
1.7	Other – Commercialisation Australia Grant	450	1,209
1.8	Other – WA Innovation Voucher Program Grant	17	17
	Net operating cash flows	(2,561)	(3,677)

		Current quarter \$A'000	Year to date (6 months) \$A'ooo
1.8	Net operating cash flows (carried forward)	(2,561)	(3,677)
1.9	Cash flows related to investing activities		
	Payment for acquisition of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	(32)	(43)
	(d) physical non-current assets	(50)	(129)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other	97	97-
	Net investing cash flows	15	(75)
1.14	Total operating and investing cash flows	(2,546)	(3,752)
	Cash flows related to financing activities		
1.15	Proceeds from issues of shares, options, etc.	10,133	10,612
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other / Transactions with Non-controlling interests		
	Net financing cash flows	10,133	10,612
	Net increase (decrease) in cash held	7,587	6,860
1.21	Cash at beginning of quarter/year to date	1,718	2,445
1.22	Exchange rate adjustments to item 1.20	-	-
1.23	Cash at end of quarter	9,305	9,305

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	93
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Consultancy services \$66k
Directors fees \$27k

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	-	-
3.2 Credit standby arrangements	-	-

The Group holds an overdraft facility of \$500,000 which is completely unused at the end of the current quarter.

Reconciliation of cash


Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	9,305	1,718
4.2	Deposits at call	-	-
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)		9,305	1,718

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	
5.2	Place of incorporation or registration	
5.3	Consideration for acquisition or disposal	
5.4	Total net assets	
5.5	Nature of business	

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does ~~does not~~* (delete one) give a true and fair view of the matters disclosed.

Sign here:  Date: 31 January 2014
(Company Secretary)

Print name: Stephen Mann

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.